



March 17, 2023

The Honorable Richard Hudson
U.S. House of Representatives
2112 Rayburn House Office Building
Washington, DC 20515

Dear Representative Hudson,

Thank you for your leadership in introducing *The Increasing Access to Biosimilars Act* (H.R. 1352). Biosimilar medicines hold enormous promise to significantly increase patient access to advanced treatments and reduce the cost of prescription drugs. Innovative solutions such as *The Increasing Access to Biosimilars Act* are needed, however, to encourage greater biosimilar adoption and use in the U.S. **On behalf of biosimilar developers and manufacturers, the Association for Accessible Medicines (AAM) and its Biosimilars Council are pleased to offer our support and endorsement of *The Increasing Access to Biosimilars Act*.**

Biosimilars are the key to reducing prescription drug costs and increasing access to care. Across the country, use of biosimilars generated over \$7 billion in savings in 2021 despite ongoing challenges to adoption.¹ To date, biosimilars have been used in more than 364 million days of patient therapy, and because of their lower costs, they have increased patient access to therapy, generating more than 150 million days of patient therapy that would not have been possible without biosimilar competition.² These savings and increased access are critical, as spending on biologic medicines now accounts for more than 45% of all spending on pharmaceuticals in the U.S.³

The Increasing Access to Biosimilars Act would take a critical step toward enhancing patient access to biosimilars through the creation of a voluntary, shared savings demonstration program in Medicare Part B. Physicians and hospitals play an important role in biosimilar adoption and research demonstrates how reimbursement policy impacts the use of biosimilars.⁴ Through a shared savings demonstration, providers would be encouraged to prescribe lower-cost biosimilar medicines and savings would be guaranteed to the federal government. An independent analysis conducted to assess the potential impact shows that a shared savings demonstration could save more than \$4 billion for seniors and \$12 billion for the Medicare program over 10 years.

¹ AAM. 2022 U.S. Generic and Biosimilar Medicines Savings Report.

<https://accessiblemeds.org/resources/reports/2022-savings-report>. Accessed March 15, 2023.

² Ibid.

³ IQVIA. Biosimilars in the United States 2023-2027. <https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2023-2027>. Accessed March 15, 2023.

⁴ IQVIA. Biosimilars in the U.S.: Reimbursement and Impacts to Uptake. <https://www.iqvia.com/locations/united-states/library/white-papers/biosimilars-in-the-us-reimbursement-and-impacts-to-uptake>. Access March 15, 2023.

The Increasing Access to Biosimilars Act would make progress on biosimilar adoption in the U.S., bringing hope to patients and improving the health of millions. We appreciate your leadership on behalf of patient access to biosimilars and look forward to working with you to advance this bipartisan legislation into law.

Sincerely,

Craig Burton

Craig Burton
Executive Director, Biosimilars Council
Senior Vice President, Policy & Strategic Allies, AAM